4-Methylhistamine (hydrochloride) – 5 mg

Brand:
Cayman
CAS:
36376-47-3
Storage:
-20
UN-No:
Non-Hazardous - /

4-Methylhistamine is a histamine H4 receptor agonist (Ki = 50 nM).{36324} It is >100-fold selective for H4 over other histamine receptors. 4-Methylhistamine inhibits CRE-β-galactosidase activity induced by forskolin (Item No. 11018) with an EC50 value of 39.8 nM in SK-N-MC cells transfected with the human H4 receptor. It induces a change in eosinophil shape (EC50 = 0.36 μM) and stimulates migration of murine bone marrow mast cells (EC50 = 12 μM), activities that can be inhibited by the histamine H4 antagonist JNJ-7777120 (Item No. 10011925). Intratracheal administration of 4-methylhistamine (10 μg/animal) reduces airway resistance and inflammation and increases the number of CD4+CD25+FoxP3+ regulatory T cells in a mouse model of allergic asthma.{36323} 4-Methylhistamine also reduces epidermal hyperplasis, hyperkeratosis, and lymphocyte infiltration and increases the number of CD4+CD25+FoxP3+ regulatory T cells in a mouse model of psoriasis induced by imiquimod (Item No. 14956).{36325}  

 

Available on backorder

SKU: 23761 - 5 mg Category:

Description

A histamine H4 receptor agonist (Ki = 50 nM); >100-fold selective for H4 over other histamine receptors; inhibits forskolin-induced CRE-β-galactosidase activity in SK-N-MC cells transfected with the human H4 receptor (EC50 = 39.8 nM); induces a change in eosinophil shape (EC50 = 0.36 μM) and stimulates migration of murine bone marrow mast cells (EC50 = 12 μM); reduces airway resistance and inflammation and increases the number of CD4+CD25+FoxP3+ regulatory T cells in a mouse model of allergic asthma when administered intratracheally at a dose of 10 μg/animal; reduces epidermal hyperplasis, hyperkeratosis, and lymphocyte infiltration and increases the number of CD4+CD25+FoxP3+ regulatory T cells in a mouse model of imiquimod-induced psoriasis


Formal name: 4-methyl-1H-imidazole-5-ethanamine, dihydrochloride

Synonyms: 

Molecular weight: 198.1

CAS: 36376-47-3

Purity: ≥95%

Formulation: A solid


Product Type|Biochemicals|Receptor Pharmacology|Agonists||Product Type|Biochemicals|Small Molecule Inhibitors|MMPs||Research Area|Immunology & Inflammation|Adaptive Immunity||Research Area|Immunology & Inflammation|Allergy||Research Area|Immunology & Inflammation|Autoimmunity||Research Area|Immunology & Inflammation|Innate Immunity||Research Area|Immunology & Inflammation|Pulmonary Diseases|Asthma